- Home
- RFAM vs INO Comparison
RFAM vs INO Comparison
Compare RFAM & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$1.07
Company Overview
Basic Information| Metric | RFAM | INO |
|---|---|---|
| Founded | 2025 | 1979 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.1M | 114.0M |
| IPO Year | 2026 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RFAM | INO |
|---|---|---|
| Price | $9.89 | $1.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 16.4K | ★ 3.6M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $9.77 | $1.03 |
| 52 Week High | $9.94 | $2.86 |
Technical Indicators
Market Signals| Indicator | RFAM | INO |
|---|---|---|
| Relative Strength Index (RSI) | 59.05 | 35.91 |
| Support Level | $9.81 | $1.03 |
| Resistance Level | $9.90 | $1.23 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 62.50 | 1.28 |
Price Performance
Historical Comparison RFAM
INO
About RFAM RF Acquisition Corp III Ordinary Shares
RF Acquisition Corp III is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.